Pharma A/p/g/g Flashcards
1
Q
Medications that may trigger Psoriasis
A
- Lithium
- Beta-blockers
- antimalarials
- angiotensin-converting enzyme inhibitor
- NSAIDs
2
Q
Hydrating Agents
A
- Water-in-oil prep
- oatmeal products
- ointments
3
Q
Anti-pruitics
A
- Antihistamines 1st Gen
- Antidepressants
4
Q
Calcineurin Inhibitors
A
- Cyclosporine
- Voclosporine
- Tacrolimus
- Pimecrolimus
5
Q
Anti-TNF Drugs
A
- Entanercept
- Infliximab
- Adalimumab
- Certolizumab pegol
- Golimumab
6
Q
Cyclosporine
A
- suppress t-cell activation
- inhibit transcription of IL-2
- inhibit production of cytokines
- immunosuppression
- Nephrotoxic, Cancer risk
7
Q
Tazarotene
A
- relative selectivity for RARb and RARg
- inhibit keratinocyte proliferation and differentiation
8
Q
Mycophenolate
A
- inhibits inosine monophosphate dehydrogenase
- inhibit proliferation of T- and B- lymphocytes
9
Q
Calcipotriene
A
- slows skin cell growth
- synthetic vitamin D3
10
Q
SE
Calcipotriene
A
- skin irritation, sting, burn
- Less common: dry skin, peeling, rash, dermatitis, worsening of psoriasis
11
Q
Anthralin
A
- reduces rapid growth of skin cells associated with plaque psoriasis
12
Q
Alefacept
A
- Binds to CD2 and inhibit leukocyte function antigen 3 and CD2 interaction
- Prevent antigen binding and T-cell activation
- Destroys T-lymph causing plaque
- increase activity of NK cells
13
Q
SE
Alefacept
A
- Sore throat, dizziness, cough, nausea, itch, muscle pain, chill
- injection site pain/ swelling
- Serious: lymphopenia, infection, cancer, allergic rxn
- Hepatic: elevate AST/ALT, fatty infiltrate, hepatitis
- avoid if blood lymphocyte < 250/ml
14
Q
IL-2
A
Necessary for T-cell activation
15
Q
Calcineurin inhibitors
A
- bind to immunophilins
- blocks effect of calcineurin
- leads to reduced IL-2 and T-cell prolif
16
Q
Tacrolimus
A
- indicated for moderate to severe atopic dermatitis
- children > 2 y.o. (0.03%)
- nephrotoxic, hemato/oncological
17
Q
Pimecrolimus
A
- mild atopic dermatitis
- > 2 y.o.
- Nephrotoxic, neospasms/infection
18
Q
Acitretin
A
- transcription regulator
- reduce keratinocytes differentiation
- slows cell reproduction
- reduce epidermal hyperplasia
19
Q
Target
TNF-alpha
A
- Certolizumab pegol
- entanercept
- adalimumab
- infliximab
- golimumab
20
Q
Target
IL-12 and 23
A
Ustekinumab
21
Q
Target
IL-23
A
- tildrakizumab
- guselkumab
- ## risankizumab
22
Q
Target
IL-17
A
- secukinumab
- ixekizumab
23
Q
SE
Ustekinumab
A
- prevent T-cell activation
- NVD, headache, tiredness
- Upper resp. infection
- flu symptoms
- ulcer, syncope, body pain/swell
- cerebal edema
- allergic rxn